Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study

Erhard van der Vries; Kai Ming Dennis Ip; Benjamin J Cowling; Jitao D Zhang; Xiao Tong; Krzysztof Wojtowicz; Martin Schutten; Charles A B Boucher

doi:10.1093/infdis/jiv375

Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study

Erhard van der Vries, Kai Ming Dennis Ip, Benjamin J Cowling, Jitao D Zhang, Xiao Tong, Krzysztof Wojtowicz, Martin Schutten, Charles A B Boucher

Department of Virosciences, Erasmus Medical Center, Erasmus University, Rotterdam, The Netherlands.
School of Public Health, The University of Hong Kong, Hong Kong SAR, China.
Department of Pharmaceutical Sciences, Translational Technologies and Bioinformatics, Roche Innovation Center Basel, Switzerland.
Infectious Diseases Discovery, Hoffmann-La Roche, Nutley, New Jersey.
Micron Research Ltd, Ely, United Kingdom.

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: Little is known about how influenza infections caused by B/Victoria and B/Yamagata virus lineages compare with respect to disease course and susceptibility to antiviral therapy.

METHODS: Data from patients with influenza B infections from the first 5 years (2009-2013) of the prospective Influenza Resistance Information Study (IRIS, NCT00884117) were evaluated. Cultured viruses were phenotypically tested for neuraminidase inhibitor (NAI) sensitivity, and sequenced to determine virus lineage (B/Victoria or B/Yamagata). Differences in clinical outcomes (viral clearance and symptom resolution) between virus lineages were assessed using Kaplan-Meier analysis.

RESULTS: In all, 914 patients were positive for influenza B by reverse transcriptase polymerase chain reaction (

RT-PCR: B/Victoria, 586; B/Yamagata, 289; not subtyped, 39); 474 were treated with antivirals. No phenotypic resistance to oseltamivir or zanamivir was found in B/Victoria or B/Yamagata viruses. Of 15 predefined resistance mutations, 2 were detected by neuraminidase sequencing: I221T had reduced sensitivity to oseltamivir, and I221V was sensitive to NAI inhibition. No consistent differences between virus lineages in times to viral clearance or to symptom or fever resolution were found in adults and adolescents or in children.

CONCLUSIONS: Influenza B virus lineage had no notable effect on disease outcomes or antiviral susceptibility in this population.

Original language	English
Pages (from-to)	183-90
Number of pages	8
Journal	Journal of Infectious Diseases
Volume	213
Issue number	2
DOIs	https://doi.org/10.1093/infdis/jiv375
Publication status	Published - 15 Jan 2016
Externally published	Yes

Keywords

Adolescent
Adult
Antiviral Agents
Child
Child, Preschool
Drug Resistance, Viral
Humans
Infant
Influenza B virus
Influenza, Human
Middle Aged
Neuraminidase
Oseltamivir
Young Adult
Zanamivir
Journal Article
Research Support, Non-U.S. Gov't

Access to Document

10.1093/infdis/jiv375

Cite this

van der Vries, E., Ip, K. M. D., Cowling, B. J., Zhang, J. D., Tong, X., Wojtowicz, K., Schutten, M., & Boucher, C. A. B. (2016). Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study. Journal of Infectious Diseases, 213(2), 183-90. https://doi.org/10.1093/infdis/jiv375

@article{3d2d2d75aecd40c2b8dd9fd8fce6ca0c,

title = "Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study",

abstract = "BACKGROUND: Little is known about how influenza infections caused by B/Victoria and B/Yamagata virus lineages compare with respect to disease course and susceptibility to antiviral therapy.METHODS: Data from patients with influenza B infections from the first 5 years (2009-2013) of the prospective Influenza Resistance Information Study (IRIS, NCT00884117) were evaluated. Cultured viruses were phenotypically tested for neuraminidase inhibitor (NAI) sensitivity, and sequenced to determine virus lineage (B/Victoria or B/Yamagata). Differences in clinical outcomes (viral clearance and symptom resolution) between virus lineages were assessed using Kaplan-Meier analysis.RESULTS: In all, 914 patients were positive for influenza B by reverse transcriptase polymerase chain reaction (RT-PCR: B/Victoria, 586; B/Yamagata, 289; not subtyped, 39); 474 were treated with antivirals. No phenotypic resistance to oseltamivir or zanamivir was found in B/Victoria or B/Yamagata viruses. Of 15 predefined resistance mutations, 2 were detected by neuraminidase sequencing: I221T had reduced sensitivity to oseltamivir, and I221V was sensitive to NAI inhibition. No consistent differences between virus lineages in times to viral clearance or to symptom or fever resolution were found in adults and adolescents or in children.CONCLUSIONS: Influenza B virus lineage had no notable effect on disease outcomes or antiviral susceptibility in this population.",

keywords = "Adolescent, Adult, Antiviral Agents, Child, Child, Preschool, Drug Resistance, Viral, Humans, Infant, Influenza B virus, Influenza, Human, Middle Aged, Neuraminidase, Oseltamivir, Young Adult, Zanamivir, Journal Article, Research Support, Non-U.S. Gov't",

author = "{van der Vries}, Erhard and Ip, {Kai Ming Dennis} and Cowling, {Benjamin J} and Zhang, {Jitao D} and Xiao Tong and Krzysztof Wojtowicz and Martin Schutten and Boucher, {Charles A B}",

year = "2016",

month = jan,

day = "15",

doi = "10.1093/infdis/jiv375",

language = "English",

volume = "213",

pages = "183--90",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "2",

}

Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study. / van der Vries, Erhard; Ip, Kai Ming Dennis; Cowling, Benjamin J et al.
In: Journal of Infectious Diseases, Vol. 213, No. 2, 15.01.2016, p. 183-90.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages

T2 - The Influenza Resistance Information Study

AU - van der Vries, Erhard

AU - Ip, Kai Ming Dennis

AU - Cowling, Benjamin J

AU - Zhang, Jitao D

AU - Tong, Xiao

AU - Wojtowicz, Krzysztof

AU - Schutten, Martin

AU - Boucher, Charles A B

PY - 2016/1/15

Y1 - 2016/1/15

N2 - BACKGROUND: Little is known about how influenza infections caused by B/Victoria and B/Yamagata virus lineages compare with respect to disease course and susceptibility to antiviral therapy.METHODS: Data from patients with influenza B infections from the first 5 years (2009-2013) of the prospective Influenza Resistance Information Study (IRIS, NCT00884117) were evaluated. Cultured viruses were phenotypically tested for neuraminidase inhibitor (NAI) sensitivity, and sequenced to determine virus lineage (B/Victoria or B/Yamagata). Differences in clinical outcomes (viral clearance and symptom resolution) between virus lineages were assessed using Kaplan-Meier analysis.RESULTS: In all, 914 patients were positive for influenza B by reverse transcriptase polymerase chain reaction (RT-PCR: B/Victoria, 586; B/Yamagata, 289; not subtyped, 39); 474 were treated with antivirals. No phenotypic resistance to oseltamivir or zanamivir was found in B/Victoria or B/Yamagata viruses. Of 15 predefined resistance mutations, 2 were detected by neuraminidase sequencing: I221T had reduced sensitivity to oseltamivir, and I221V was sensitive to NAI inhibition. No consistent differences between virus lineages in times to viral clearance or to symptom or fever resolution were found in adults and adolescents or in children.CONCLUSIONS: Influenza B virus lineage had no notable effect on disease outcomes or antiviral susceptibility in this population.

AB - BACKGROUND: Little is known about how influenza infections caused by B/Victoria and B/Yamagata virus lineages compare with respect to disease course and susceptibility to antiviral therapy.METHODS: Data from patients with influenza B infections from the first 5 years (2009-2013) of the prospective Influenza Resistance Information Study (IRIS, NCT00884117) were evaluated. Cultured viruses were phenotypically tested for neuraminidase inhibitor (NAI) sensitivity, and sequenced to determine virus lineage (B/Victoria or B/Yamagata). Differences in clinical outcomes (viral clearance and symptom resolution) between virus lineages were assessed using Kaplan-Meier analysis.RESULTS: In all, 914 patients were positive for influenza B by reverse transcriptase polymerase chain reaction (RT-PCR: B/Victoria, 586; B/Yamagata, 289; not subtyped, 39); 474 were treated with antivirals. No phenotypic resistance to oseltamivir or zanamivir was found in B/Victoria or B/Yamagata viruses. Of 15 predefined resistance mutations, 2 were detected by neuraminidase sequencing: I221T had reduced sensitivity to oseltamivir, and I221V was sensitive to NAI inhibition. No consistent differences between virus lineages in times to viral clearance or to symptom or fever resolution were found in adults and adolescents or in children.CONCLUSIONS: Influenza B virus lineage had no notable effect on disease outcomes or antiviral susceptibility in this population.

KW - Adolescent

KW - Adult

KW - Antiviral Agents

KW - Child

KW - Child, Preschool

KW - Drug Resistance, Viral

KW - Humans

KW - Infant

KW - Influenza B virus

KW - Influenza, Human

KW - Middle Aged

KW - Neuraminidase

KW - Oseltamivir

KW - Young Adult

KW - Zanamivir

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1093/infdis/jiv375

DO - 10.1093/infdis/jiv375

M3 - Article

C2 - 26160744

SN - 0022-1899

VL - 213

SP - 183

EP - 190

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 2

ER -

Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study

Abstract

Keywords

Access to Document

Fingerprint

Cite this